Circulating tumor DNA for disease monitoring in bone sarcomas: clinical applications, challenges, and future perspectives

Bone sarcomas (BSs) are rare, biologically heterogeneous malignancies for which disease recurrence and metastatic progression remain major determinants of poor patient outcomes. Therefore, reliable tools to aid the assessment of response to treatment, the detection of molecular residual disease (MRD) and the timely identification of disease recurrence are essential but still limited to conventional imaging and tissue-based approaches. Circulating tumor DNA (ctDNA), a tumor-derived fraction of cell-free DNA detectable through liquid biopsy (LB), has emerged as a promising non-invasive biomarker capable of capturing dynamic molecular changes throughout the course of the disease. Increasing evidence supports its potential for postoperative surveillance, early relapse detection, response assessment and longitudinal monitoring. Nevertheless, several biological and technical barriers, including low ctDNA abundance, genomic heterogeneity among BS subtypes, and the lack of standardized analytical workflows continue to hinder widespread clinical implementation. This mini review provides an overview of the current landscape of ctDNA applications for MRD detection and disease monitoring in BSs, examines the key challenges to its clinical adoption, explores technological advances and outlines ongoing clinical studies that are expected to shape its future role in patient management.

Authors

Institutions

Publication Details

Journal
Frontiers in Oncology
Published
2026-11-13
DOI
https://doi.org/10.3389/fonc.2026.1996053
Primary Topic
Sarcoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Circulating tumor DNA for disease monitoring in bone sarcomas: clinical applications, challenges, and future perspectives

Anastasia Constantinidou, Maria Stavrou, Tatiana Nicolaou, Maria Georgalli
6 links
Frontiers in Oncology
Sarcoma Diagnosis and Treatment
article

Circulating tumor DNA for disease monitoring in bone sarcomas: clinical applications, challenges, and future perspectives

Anastasia Constantinidou, Maria Stavrou, Tatiana Nicolaou, Maria Georgalli
article en

Abstract

Bone sarcomas (BSs) are rare, biologically heterogeneous malignancies for which disease recurrence and metastatic progression remain major determinants of poor patient outcomes. Therefore, reliable tools to aid the assessment of response to treatment, the detection of molecular residual disease (MRD) and the timely identification of disease recurrence are essential but still limited to conventional imaging and tissue-based approaches. Circulating tumor DNA (ctDNA), a tumor-derived fraction of cell-free DNA detectable through liquid biopsy (LB), has emerged as a promising non-invasive biomarker capable of capturing dynamic molecular changes throughout the course of the disease. Increasing evidence supports its potential for postoperative surveillance, early relapse detection, response assessment and longitudinal monitoring. Nevertheless, several biological and technical barriers, including low ctDNA abundance, genomic heterogeneity among BS subtypes, and the lack of standardized analytical workflows continue to hinder widespread clinical implementation. This mini review provides an overview of the current landscape of ctDNA applications for MRD detection and disease monitoring in BSs, examines the key challenges to its clinical adoption, explores technological advances and outlines ongoing clinical studies that are expected to shape its future role in patient management.

Frontiers in OncologyVol. 16
University of Cyprus (CY), Bank of Cyprus Oncology Center (CY)
Good health and well-being
Sarcoma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon